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Abstract 38 
 39 
Background 40 
Complex Regional Pain Syndrome (CRPS) is a rare, severe post-traumatic pain 41 
condition affecting distal limbs and two small trials have shown efficacy of low-42 
dose intravenous immunoglobulin in longstanding disease. 43 
 44 
Objective 45 
To confirm the efficacy of low-dose immunoglobulin treatment when compared 46 
to placebo treatment to reduce pain over 6 weeks, in adult patients suffering 47 
from CRPS of between 1-5 years’ duration.  48 
 49 
Design 50 
This was a 1:1 online-randomized, placebo-controlled multi-center trial over 6 51 
weeks, with an optional 6-week open extension. Patients were randomized 52 
between 27.08.2013 and 28.10.2015, and the last patient completed follow-up 53 
on 21.03.2016. Patients, providers, researchers, and outcome-assessors were 54 
blinded to the treatment-assignment (ISRCTN, 42179756). 55 
 56 
Setting 57 
Seven secondary and tertiary care pain management centers in the United 58 
Kingdom.   59 
 60 
Participants  61 
Patients with moderate or severe CRPS of between1-5 years duration.  62 
 63 
Interventions 64 
0·5g/kg intravenous immunoglobulin (IVIg), or visually indistinguishable 0.1% 65 
albumin in saline placebo, on day 1 and day 22 after randomization. 111 patients 66 
were randomized.  67 
 68 
Measurements 69 
The primary outcome was the 24h average pain intensity measured daily 70 
between days 6 and 42, on an 11-point (0-10) numeric rating scale.  71 
 72 
Results 73 
108 eligible patients were analyzed for the primary outcome. The mean of the 74 
(average) pain scores was 6.9 (SD 1·5) for Placebo and 7.2 (1.3) for IVIg and the 75 
adjusted difference in means was 0·27 (95% CI -0.25 to 0.80; P = 0.30), which 76 
excludes the pre-specified clinically important difference of -1.2. In the open 77 
extension, 12 of the 67 patients who were treated with two infusions had at least 78 
2 points pain reduction compared to their baseline pain. There were 6 serious 79 
 3 
adverse events – two in the blinded phase (1 placebo, 1IVIg) and four in the open 80 
phase (4 IVIG). 81 
 82 
Limitations 83 
Results do not apply to patients with CRPS >5 years duration. 84 
 85 
Conclusion 86 
Low-dose immunoglobulin treatment over 6 weeks was not effective in relieving 87 
pain in patients with moderate to severe CRPS of 1-5 years’ duration.  88 
 89 
Funding source 90 
Medical Research Council/National Institute for Health Research Efficacy and 91 
Mechanism Evaluation Program, Pain Relief Foundation, Biotest United Kingdom 92 
Ltd 93 
 94 
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Introduction 96 
 97 
Complex Regional Pain Syndrome (CRPS) is a rare chronic pain condition 98 
(population prevalence <1:2000) arising after trauma to distal limbs (1, 2). The 99 
CRPS diagnosis is clinical, based on the assessment of sensory-, motor- and 100 
autonomic abnormalities in the affected limb (3). Most patients improve 101 
spontaneously, however those 15% with still ongoing symptoms 1 year after 102 
onset have amongst the lowest quality of life in medical conditions, and their 103 
prognosis is poor (4, 5). Treatment with analgesic drugs such as antidepressants, 104 
or anticonvulsants is rarely effective (6). Recommended is multidisciplinary care, 105 
however many patients will not achieve pain relief (7).  106 
Following a chance observation, we conducted a prospective open study, and a 107 
small randomized crossover trial, where low-dose intravenous immunoglobulin 108 
substantially reduced pain in this patient group. The proportion of patients with 109 
profound pain relief of >50% was 25% in both studies (8, 9).  110 
The phase III ‘Low-dose Immunoglobulin in longstanding Complex Regional Pain 111 
Syndrome’ (LIPS) randomized controlled trial was conducted to confirm the 112 
efficacy of repeated-dose treatment with low-dose intravenous immunoglobulin 113 
(IVIg) over placebo in a large group of patients with longstanding CRPS. The 114 
primary outcome was the pain intensity measured daily over a 6-week period 115 
following infusion. This was compared between immunoglobulin and placebo 116 
groups.  117 
 118 
 119 
Methods 120 
 121 
Design Overview 122 
 123 
In this parallel group trial patients with Complex Regional Pain Syndrome were 124 
randomly assigned in 1:1 allocation to receive either of two infusions of 0·5 g/kg 125 
intravenous immunoglobulin (IVIG), or placebo; all patients were offered an 126 
open label extension of two IVIg infusions. Providers, researchers, and outcome 127 
assessors were blinded to the treatment assignments. Ethics approval was given 128 
(12/EE/0164, East of England Ethics, Welwyn). Patients were provided with 129 
patient information leaflets about the trial, and interested patients gave written 130 
informed consent. The study protocol has been published (10) 131 
 132 
Setting and participants 133 
 134 
The study recruited across 7 UK secondary and tertiary care pain treatment 135 
centers. Participants were recruited from the study centers’ internal databases, 136 
and from new patients referred to these seven study centers. To enhance 137 
recruitment, the study was regularly publicized in UK Pain Medicine professional 138 
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journals, through letters to each English Specialist Pain Clinic, on social network 139 
sites, and with UK CRPS patient organizations.  140 
 141 
Eligible participants were non-pregnant adults with moderate or severe CRPS 142 
(Budapest research criteria(3)). The CRPS severity cutoff was concealed, and 143 
determined by a mean pain intensity of five or higher on an 11-point (0-10) 144 
Numeric Rating Scale (NRS) over the first seven daily entries into pain diaries 145 
during screening, with no single entry below 4. A pain intensity of 4/10 is 146 
considered a cut point between mild and moderate pain (11). The Budapest 147 
research criteria require the presence of at least one regional sign, in at least 2 of 148 
4 diagnostic categories, i.) sensory abnormalities such as allodynia, ii.) swelling 149 
or sweating, iii.) colour or temperature changes, iv.) motor or trophic changes; 150 
additionally required is the report of symptoms in all 4 categories. All 151 
recruitment centers used these criteria. Patients with either CRPS type I 152 
(without-), or II (with nerve injury) were eligible.  Patients had between 1-5 153 
years’ disease duration, and no other pains which in the study doctor’s opinion 154 
might interfere with the patients’ own assessment of CRPS-pain changes.  155 
Before enrolment, patients had tried tricyclic antidepressants, gabapentinoids, 156 
mild and strong opioids, and they had received specialized pain physiotherapy, if 157 
not refused by them, or contraindicated. Patients with implanted spinal cord 158 
stimulator were eligible if they met pain intensity criteria with the stimulator 159 
turned on. Patients continued with their usual exercises and medications. 160 
Further detail on inclusion and exclusion criteria is provided in the study 161 
protocol (10).   162 
 163 
After consent and screening for eligibility, suitable patients completed a 164 
screening diary for 7 days, and were then telephoned to ascertain their diary 165 
values; the suitable patients were randomized 10-21 days after screening (=day 166 
0).  167 
 168 
Randomisation and Interventions 169 
 170 
Participants were individually randomly assigned (1:1) to IVIg or placebo by site 171 
staff via an independent online randomization system, using block 172 
randomization with randomly varying block sizes, stratified by study center.   173 
Blinding was achieved by preparing the IVIg (0·5 g/kg IVIg) or placebo solution 174 
(0·.1% albumin in normal saline) into bottles of identical appearance. Upon 175 
notification, non-blinded dispensing site pharmacists removed the bottle-label 176 
indicating the trial arm before dispensing. All other study site staff, the trial 177 
manager / site monitor, statistician and Chief Investigator remained blinded to 178 
the patients’ treatment assignments until database-lock. No participants 179 
required emergency un-blinding.    180 
 181 
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Blinded infusions were scheduled on days 1 and 22 post-randomization. A pre-182 
determined time window around the infusion days provided flexibility (first 183 
infusion up to 5 working days, second infusion day 22 +/- 1day). The primary 184 
outcome period, days 6-43 after randomization, remained fixed and was thus 185 
independent of the actual infusion dates.  186 
Patients who completed the blinded phase were offered a choice to have open 187 
label immunoglobulin infusions on days 43 and 64 post-randomization. The 188 
dosages prescribed were within normal, weight-determined clinical limits 189 
(0.5g/kg) for low-dose treatment.  190 
 191 
Outcomes and Follow-up 192 
 193 
Paper diaries documenting the participants’ average 24h pain score on a 11-194 
point (0-10) numeric rating scale were self-administered by the participants 195 
from day 1 to 43 post-randomization (example diary provided in the Appendix), 196 
and a weekly pain score was documented for 9 weeks further. Those who 197 
decided to have two open infusions after the end of the blinded phase completed 198 
24h diaries to day 84, and nine weekly diaries thereafter. These were 11-point 199 
numeric rating scale scores, with 0=no pain, 10=pain as bad as you can imagine.  200 
Patients completed questionnaires at screening, and day 43, assessing their 201 
multidimensional pain experience. At these two time-points we also measured 202 
skin temperature of both the CRPS affected and contralateral limbs (protocol in 203 
the Appendix). 204 
Safety bloods (serum immunoglobulin, full blood count, creatinine, urea and 205 
electrolytes), and where applicable pregnancy tests were collected at the 206 
screening visit to determine the patient’s eligibility. Site staff contacted 207 
participants twice following each infusion, to confirm adherence to completing 208 
the pain diaries, and to document any adverse events.  209 
 210 
The primary outcome measure was the average 24h pain intensity measured 211 
daily from day 6 to 42. The interval starting day 6 was pre-specified to exclude 212 
the time period of early, unspecific, temporary pain increases, such as headaches 213 
(8). Secondary outcomes were the pain interference measured using the 214 
interference subscale of the Brief Pain Inventory (12), and quality of life 215 
(Euroqol EQ-5D-5L) (13). All other outcomes were exploratory. 216 
Multidimensional assessment tools were used, in line with consensus 217 
recommendations for pain trials (14). Details are provided in the Appendix, and 218 
in the published protocol (10). 219 
 220 
Reasons for withdrawal from randomized treatment were reported at days 22 221 
and 43 post-randomization. Adverse events and reactions were recorded by 222 
patients in their diaries, and were transcribed at 22 and 43 days post 223 
randomization. In addition, study nurses queried adverse events using open 224 
 7 
ended questions as part of scheduled telephone calls at 2 and 5 days after each 225 
infusion. A study doctor rated the severity and causality of each event in 226 
categorical scales. Open label infusion adverse events, reported from 43 to 85 227 
days post randomization, were tabulated separately. Serious Adverse Events 228 
(SAEs) were monitored for 21 days after the final dose of IVIg (or placebo) or 229 
until resolution.  230 
 231 
Statistical Analysis 232 
 233 
The sample size was based on the following assumptions from a pilot study (8): 234 
122 participants were required to detect a clinically meaningful difference on a 235 
group level (15)) in pain score of 1.2 using a two-sample t-test assuming 5% 236 
statistical significance, 85% power and a common standard deviation of 2·2 (as 237 
in this previous study). Assuming 10% loss to follow-up and a 5% non-238 
compliance increased this number to 152 participants. We intended to collect 37 239 
measurements of pain intensity (the primary outcome) per participant and 240 
analyze the outcome using a mixed effects regression model. Therefore, the 241 
sample size was reduced based on these extra measurements. From the pilot 242 
study (8) the correlation between a patient's measures was assumed to be 0.7, 243 
hence the multiplying factor was (1+(37-1)x0.7)/ 37 =0.71) Therefore the total 244 
required sample size was calculated at  152 x 0.71 = 108 participants (54 245 
participants per study arm). 246 
 247 
All statistical analyses were conducted using Stata version 14. The primary 248 
outcome was analyzed using a random-intercepts mixed model (Stata: mixed) to 249 
establish any difference between pain scores after IVIg and placebo. In detail, 250 
this model contained fixed effects for treatment and study center and assumed 251 
an exchangeable correlation structure between the 37 repeated outcome 252 
measurements for a patient. Modeling assumptions were checked: level 1 and 2 253 
residuals were checked for normality. The primary analysis sample was an 254 
intention to treat (ITT) sample based on all randomized, eligible patients. No 255 
imputation was performed. As a secondary analysis, we calculated the 256 
proportion of participants in each arm that achieved 50% or 30% pain relief 257 
based on the average pain level entered on days 6-42, compared to their baseline 258 
level of pain (the average pain level recorded during the first 7 days of the 259 
screening period). Pain reduction of 30% represents a clinically meaningful 260 
effect on an individual level (16)).  261 
 262 
The following sensitivity analyses were performed: (i) A fixed effect was added 263 
to the mixed model for baseline pain score; (ii) A fixed effect was added to the 264 
mixed model for disease duration; (iii) Three patients who were incorrectly 265 
consented into the trial after not meeting the inclusion criteria were included in 266 
the analysis. Possible subgroup effects based on study center, disease duration, 267 
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gender, allergy status, IgG plasma level, anxiety and depression, and CRPS type 268 
were investigated separately using exploratory plots and by fitting mixed models 269 
that included interaction terms between the factor and treatment. 270 
 271 
The secondary outcomes Brief Pain Inventory interference scores and Quality of 272 
Life (EQ-5D-5L), and also McGill Pain Questionnaire (Short Form) descriptor 273 
terms (17) and limb temperature were analysed using linear regression models 274 
(Stata: regress) with covariates for treatment and study center.  275 
 276 
In those who decided to receive both open infusions, and who had at least 30% 277 
or 2 NRS points average pain relief from 6 to 20 days after their last open 278 
infusion as compared with baseline, the time between the last open infusion, and 279 
the first period with average weekly pain equaling or exceeding baseline -1NRS 280 
point was calculated as the IVIg effect duration. As the study ended on day 148 281 
(12 weeks after the second open infusion), later effects were not recorded.  282 
 283 
A Data Monitoring Committee had access to the un-blinded data and monitored 284 
the progress of the trial in terms of safety and ethical issues. A blinded interim 285 
analysis was performed for safety after half of participants completed the trial. 286 
The stopping rule was based on detecting an effect in favor of placebo at the 5% 287 
significance level. The Data Monitoring Committee reviewed the results of the 288 
analysis and recommended continuation of the trial.  289 
This trial is registered with ISRCTN, 42179756.  290 
 291 
Role of the funding source 292 
 293 
This project was funded by the Efficacy and Mechanism Evaluation Program, an 294 
Medical Research Council and National Institute for Health Research partnership, 295 
and the Pain Relief Foundation Liverpool. Biotest United Kingdom Ltd provided 296 
the active study medication at no cost. The funders had no role in the study 297 
design, data collection, data analysis, data interpretation or writing of the report. 298 
The corresponding author and the Trial Statistician had full access to all the data 299 
in the study and the corresponding author was responsible for the final 300 
submission of the publication.  301 
 302 
 303 
Results 304 
 305 
Patients 306 
 307 
Between 27th August 2013 to 28th October 2015, 121 patients from 7 sites were 308 
screened for eligibility. Of these, 111 were randomized to one of the two trial 309 
arms. 56 were randomized to Placebo and 55 were randomized to IVIg. Three 310 
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patients were randomized in error. Two had an average baseline pain score 311 
(over the first 7 days of screening) below 5 and one had a disease duration of 312 
less than 12 months. These 3 patients (all randomized to IVIg) are excluded from 313 
the primary analysis. Twelve patients withdrew from study medication before 314 
the end of the blinded phase (day 42). Two of these patients did not receive their 315 
first infusion and supplied no outcome pain data and three further patients 316 
received their first infusion but also did not supply any outcome pain data. The 317 
remaining 7 patients received their first infusion and all completed their pain 318 
diaries for at least 2 weeks. Six of these 12 patients indicated an adverse event as 319 
reason for their withdrawal (3 on Placebo and 3 on IVIg), one patient wished to 320 
pursue an alternative therapy, two patients stated problems with travel 321 
arrangements, and three patients gave no reason. The primary analysis was 322 
performed on 108 patients, with 56 in Placebo and 52 in IVIg (Figure 1 near 323 
here).  324 
  325 
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Figure 1. 326 
 327 
 328 
 329 
Figure 1. Consort Flow diagram LIPS trial. IVIg=intravenous immunoglobulin 330 
 331 
 332 
Baseline characteristics for the 108 patients included into the primary (ITT) 333 
analysis are shown in Table 1. Balance was achieved for most parameters, 334 
although there was a slight gender imbalance (Table 1 near here). Apart from 335 
one case of stable Crohn’s disease, participants had no severe, or multiple 336 
concomitant autoimmune disorders (not shown). 337 
  338 
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Table 1. Patient baseline characteristics 339 
 340 
 Placebo (n=56) IVIg (n=52) 
Age, years   
Mean (SD) 41·0 (12·5) 43·7 (11·6) 
   
Gender   
Male 14 (25%) 19 (37%) 
Female 42 (75%) 33 (63%) 
   
Ethnicity   
Asian 0 (0%) 2 (4%) 
White 55 (98%) 50 (96%) 
Other 1 (2%) 0 (0%) 
   
Disease duration, years   
Mean (SD) 2·5 (1·2) 2·3 (1·2) 
Median (Q1,Q3) 2.5 (1,4) 2 (1,3) 
   
CRPS type   
I 49 (88%) 44 (85%) 
II 6 (11%) 6 (12%) 
Undecided 1 (2%) 2 (4%) 
   
Limb involvement   
1 limb 43 (77%) 41 (79%) 
2/3/4 limbs 10/0/3 8/2/1 
   
Average Baseline Pain   
Mean (SD) 7·4 (1·1) 7·5 (1·0) 
Median (Q1, Q3) 7.4 (6.7, 8.1) 7.6 (7, 8.3) 
   
Quality of life   
EQ-5D-5L: Mean (SD) 0·34 (0·28) 0·33 (0·27) 
   
Pain Interference   
Brief Pain Inventory: Mean 
(SD) 
7·32 (1·72) 7·47 (1·63) 
   
Limb Temperature   
Mean (SD) difference with 
non-affected side 
- 0·75 (0.20) C -0·90 (0.24) C 
Percentage of patients with 
lower temperature in affected 
side 
68% 70% 
Table 1: Baseline characteristics by trial arm for patients analyzed for the primary Intention to treat (ITT) 341 
analysis (n=108).  SD=Standard Deviation. Values are either Mean (SD), Median (Q1=quartile 1, Q3) or 342 
Number (%). Type I/II CRPS is not/is associated with injury to a major nerve.  Baseline data are from 108 343 
patients, excepting limb temperature, which was measured only in patients who had a healthy contra-344 
lateral limb, and who could tolerate the procedure (placebo n=47; IVIg n=46).    345 
 346 
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There was no indication that patients identified their treatments when assessed 347 
after the first infusion (Table 2), or after the second infusion (not shown); hence 348 
we were satisfied that blinding was successful. (Table 2 near here) 349 
 350 
Table 2. Success of blinding. 351 
 352 
 Trial Arm 
Guess Placebo IVIg 
Prescribed IVIg 5 (9%) 5 (10%) 
Don’t know 44 (80%) 35 (69%) 
Prescribed placebo 6 (11%) 11 (22%) 
Total 56 52 
Table 2: Success of blinding at visit 2, after the first infusion assessed by the 108 patients included into the 353 
primary analysis 354 
 355 
 356 
Primary Outcome  357 
 358 
103 patients provided at least 14 daily pain intensity scores for the primary 359 
outcome between days 6-42, and 5 supplied none (Appendix Table 1). The 360 
average pain scores over days 1-84 for each patient, by trial arm, are shown in 361 
Figure 2 for the 108 patients included in the primary ITT analysis (Figure 2 near 362 
here).  363 
 364 
 365 
Figure 2  366 
 367 
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Figure 2. Average pain for each day by trial arm (day 1 - 84). Values on the Y-axis reflect average 24h pain 368 
intensity numeric rating scale scores (0=no pain, 10=pain as bad as you can imagine). The patient numbers 369 
for each time point are as follows: screening n=108; day 1 n=93; day 6 n=101; day 22 n=93; day 43 n=85; 370 
day 84 n=62. Note, screening started at most 21 days before randomization (randomization=day 0). 371 
 372 
It is clear that average pain scores per patient were very similar for each 373 
treatment group.  The mean of these (average) pain scores was 6·9 (SD 1·5) for 374 
Placebo and 7·2 (1·3) for IVIg and the adjusted difference in means was 0·27 375 
(95% CI -0.25 to 0·80; p = 0·30). Therefore, there is no significant evidence of a 376 
treatment effect at the 5% level. In addition, the confidence interval excludes the 377 
clinically important difference of -1.2. Sixty-nine (67%) patients had lower pain 378 
scores following treatment.  This was very similar in both arms: 35/53 (66%) for 379 
Placebo and 34/50 (68%) for IVIg. Four patients achieved 30% pain reduction, 3 380 
in Placebo and 1 in IVIg.  In addition to these four patients, just one patient, in 381 
Placebo achieved 50% pain reduction. The average pain scores during the 382 
primary outcome period (day 6 to day 42) were fairly constant (Figure 2). 383 
 384 
The treatment effect changed little when the model was adjusted for average 385 
baseline pain and disease duration.  Similarly, results were only minimally 386 
changed when we included the three patients who had been randomized in 387 
error. One patient in the placebo group recorded very low pain scores (mean 388 
pain = 0·9 from 37 measurements).  Omitting this patient from the primary 389 
analysis reduces the overall treatment effect in favor of placebo by a third (0·17 390 
(95% CI: -0·30 to 0·64, p=0·49). 391 
 392 
There was no evidence of any subgroup effects based on disease duration 393 
(p=0·164), gender (P=0·76), allergy status (P=0·49), low baseline IgG 394 
(<10/>=10, p=0·19) or HADS sub-scores for anxiety (P = 0·37) and depression (P 395 
= 0·77). In addition, there was no statistical evidence for a difference in 396 
treatment effects between the 7 study sites (p=0·68), however we note that this 397 
study was not powered for these comparisons (Appendix Table 2). There was 398 
weak evidence that treatment differs by CRPS type (P=0·016) with a possible 399 
positive effect for CRPS II patients (n=14, three patients with ‘undecided’ CRPS 400 
type were omitted from this analysis).   401 
 402 
Secondary Outcomes 403 
 404 
At baseline, patients had a very low quality of life, and high pain interference, 405 
consistent with reports for patients with persistent CRPS (Table 1)(5). The mean 406 
quality of life at baseline (EQ-5D-5L) was around 0·33 in both groups.  This 407 
increased slightly following treatment with means of 0.37 (SD 0.29) for Placebo 408 
and 0.41 (0·27) for IVIg.  The adjusted difference in means was 0·03 (95% CI -409 
0·08 to 0·15; p = 0·58).  The number of patients with a meaningful improvement, 410 
of >=0·1 points was similar between groups (20/51 (39%) Placebo, 18/43 411 
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(42%) IVIg). At baseline, the mean interference subscale of the Brief Pain 412 
Inventory was around 7.3 in both groups.  This decreased to 6·89 (SD 2·08) for 413 
placebo and 7·24 (1·54) for IVIg and the adjusted difference in means was 0·35 414 
(95% CI -0·43 to 1·13; p = 0·38).  415 
 416 
Exploratory Outcomes and open extension 417 
 418 
One patient in the IVIg group stopped-, whereas three patients in the IVIg group, 419 
and one patient in the placebo group started an analgesic medication. 420 
A summary of exploratory-, and open extension outcomes are given in the 421 
Appendix.  422 
 423 
Adverse Events 424 
 425 
Harms from the study medication in the parallel phase are summarize in Table 3. 426 
There were two serious adverse events in the blinded phase. One patient on 427 
placebo developed severe headaches and vomiting, and another patient in the 428 
IVIG group developed severe headaches. Both required hospitalization, but were 429 
discharged the next day and quickly recovered. Open phase events are detailed 430 
in the Appendix (Table 3 near here). 431 
 432 
Table 3. Harm reported during the blinded phase of the study* 433 
 434 
Adverse Event IVIg 
(n = 52) 
Placebo 
(n = 56) 
Death - - 
Withdrawal from study medication due to adverse event 3 (6) 3 (5) 
≥ 1 adverse event 39 (75) 40 (71) 
Serious adverse event 1 (2) 2 (4) 
- Headache 1 (2) 1 (2) 
  -      Vomiting - 1 (2) 
* Values are numbers (percentages) 435 
 436 
 437 
Conclusions 438 
 439 
In this phase III randomized controlled trial, treatment with two, low doses 440 
(0·5g/kg/dose) of intravenous immunoglobulin, over 6 weeks had no significant 441 
effect on patients’ pain intensities. In the active group, no patient reported 442 
substantial pain reduction contrasting results from previous smaller studies.  443 
 444 
We had conducted this trial to obtain definite evidence for the low-dose IVIg 445 
treatment, based on preliminary data indicating efficacy. Immunoglobulin 446 
treatment did not reduce pain, nor improve any of the secondary or exploratory 447 
outcomes. We found no predictive marker for a better treatment response 448 
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amongst pre-specified parameters. The small pain reduction of 7·8% in the 449 
placebo group is consistent with recent meta-analysis data indicating that 450 
patients with persistent CRPS have a relatively stable natural course and only a 451 
small placebo effect in clinical trials (18). 452 
 453 
English-language MEDLINE search about intravenous immunoglobulin 454 
treatment for CRPS returned 4 primary reports (two case reports, of which one 455 
is with high-dose treatment in acute CRPS (19, 20)), our case series (9), our prior 456 
randomized controlled trial (RCT) (8), and our report on maintenance therapy in 457 
two patients (21), overall n=25 cases). Each report indicated IVIg efficacy in 458 
CRPS. Additionally, other authors have highlighted that they have successfully 459 
been using IVIg in their patients (22, 23), without providing details. It is not 460 
known why the results in the current RCT differ so markedly from these prior 461 
studies. Small trials, particularly when associated with only few primary events, 462 
are subject to biases, including selection and exaggeration. The importance of 463 
responder analysis to identify predictive factors for a response is evident, 464 
however our results suggest that responders to low-dose IVIg will be rare.  465 
 466 
Our findings add to negative evidence for the efficacy of anti-inflammatory 467 
treatments in persistent CRPS including lenalidomide, infliximab, intrathecal 468 
steroids, and oral steroids (24-27).  Recent in vivo and in vitro studies have 469 
suggested a role for functionally active, non-inflammatory autoantibodies (28-470 
30), indicating that patients might respond to immune therapies which either 471 
directly reduce autoantibody plasma levels, or target lymphocytes (23, 31-34).  472 
 473 
Study strengths include its multicenter-nature, size for a rare disorder – the 474 
largest academic trial in persistent CRPS to date, recruitment over the pre-475 
specified, relatively short time-period, successful blinding, and high patient 476 
adherence; the latter resulted in high data quality minimizing uncertainty 477 
(Appendix Table 1). The patient demographics are typical for this group and 478 
active and comparator groups are well balanced. The consistently negative 479 
primary, and pre-defined secondary endpoints provide clear, definite evidence 480 
that this intervention is not effective in this group.  481 
 482 
Limitations include that our data are not applicable to the groups of patients with 483 
either >5 years, or <1 year disease duration, which had been excluded.  484 
Our results do not extend to treatment with full-dose IVIg, e.g. 2g/kg/infusion. 485 
The use of albumin as control treatment might have confounded treatment 486 
effects because of its possible activity in immune-mediated disorders (35). We 487 
chose a very low albumin concentration (0.1%), and the overall placebo 488 
response in this trial was low. We infer that our results are not substantially 489 
confounded by the use of albumin placebo. Our study was not powered to detect 490 
any subgroup effects.  491 
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 492 
In conclusion, in this randomized controlled trial in 108 patients, once-repeated 493 
treatment with low-dose (0·5g/kg) intravenous immunoglobulin over 6 weeks 494 
did not reduce pain in patients with Complex Regional Pain Syndrome of 495 
between 1-5 years’ duration. No patient experienced >50% pain relief on drug 496 
contrasting results from earlier studies. Alternative analgesic technologies are 497 
required to allow treatment of this often-devastating condition.  498 
 499 
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